BME seminar series (Wenqing Gao) (1)

Background

Immunoengineering has significantly advanced cancer immunotherapy, including CAR-T, and its future prospects are limitless. The current trend of CAR-T application is autoimmune diseases and other CAR effectors in tissue repairing and senolytic. Wenqing Gao opened the new venue of immunoengineering during her training with Jonathan Kipnis. By profiling T-cells in the central nervous system injury, she identified the neuroprotective CD4+ T-cells. mRNA delivery of specific TCR generated such neuroprotective CD4+ T-cells, resulting in CNS injury recovery. This new T-cell therapy for CNS injury is published in Nature, 2024 (Gao et al.).